T9191
Anti-TRAIL antibody produced in rabbit
IgG fraction of antiserum, buffered aqueous solution
Synonym(s):
Anti-Apo-2L
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
MDL number:
UNSPSC Code:
12352203
biological source
rabbit
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 35 kDa
species reactivity
human
technique(s)
microarray: suitable
western blot: 1 μg/mL using human HeLa cell extract
UniProt accession no.
shipped in
wet ice
storage temp.
2-8°C
Gene Information
human ... TNFSF10(8743)
Immunogen
synthetic peptide corresponding to amino acids 261-277 of the C-terminal region of human TRAIL (TNF-Related Apoptosis-Inducing Ligand).
Physical form
Supplied as 1.0 mg/ml of IgG fraction of antiserum in phosphate buffered saline containing 0.02% sodium azide
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hanjie Yi et al.
Oncology letters, 16(4), 4768-4772 (2018-09-15)
Non-small cell lung cancer (NSCLC) presents severe threats to the lives of patients. Gefitinib is one of the first-line drugs available for the treatment of NSCLC in the clinical setting. The present study investigated the effects of gefitinib on NSCLC
Ufuk Mert et al.
Cancers, 11(8) (2019-08-17)
Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-R1/-R2 as targets for anti-cancer therapy, yet the corresponding clinical trials were disappointing. Meanwhile, it emerged that
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service